OncoMatch/Clinical Trials/NCT05653635
Contribution From PET-DOPA in Glioblastoma Re-irradiation - A Randomized Phase II Study
Is NCT05653635 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies non-drug interventions for glioblastoma.
ReciDOPA is a phase II, single-stage randomized, multicenter, prospective trial assessing the efficacy of an irradiation protocol based on Intensity-modulated radiation therapy with simultaneous-integrated boost guided by FDOPA-PET in patient with recurrent glioblastoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Glioblastoma
Disease stage
Required: Stage IV (WHO)
Grade: IV (WHO)
Glioblastoma, World Health Organization (WHO) grade IV, histologically proven
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: radiation therapy — in previsional re-irradiated site or in the vicinity (5 to 7 cm)
Past irradiation in previsional re-irradiated site or in the vicinity (5 to 7 cm)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05653635 currently recruiting?
Yes, this trial is currently recruiting patients.
Is prior treatment required for enrollment?
Yes. Patients must have previously received radiation therapy.
What disease stage is eligible?
Stage IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages